Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments
| العنوان: | Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments |
|---|---|
| المؤلفون: | Canan G. Nebigil, Laurent Désaubry, Anais Audebrand |
| المساهمون: | Laboratoire de Cardio-Oncologie et Chimie Médicinale, Centre National de la Recherche Scientifique (CNRS), Nanomédecine Régénérative (NanoRegMed), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM) |
| المصدر: | Frontiers in Cardiovascular Medicine, Vol 6 (2020) Frontiers in Cardiovascular Medicine Frontiers in Cardiovascular Medicine, Frontiers Media, 2020, 6, pp.194. ⟨10.3389/fcvm.2019.00194⟩ Frontiers in Cardiovascular Medicine, Frontiers Media, 2020, 6, ⟨10.3389/fcvm.2019.00194⟩ |
| بيانات النشر: | Frontiers Media S.A., 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, lcsh:Diseases of the circulatory (Cardiovascular) system, Myocarditis, Aucun, cardiotoxicity, [SDV.CAN]Life Sciences [q-bio]/Cancer, melatonin, Review, 030204 cardiovascular system & hematology, Pharmacology, Cardiovascular Medicine, GPCRs, 03 medical and health sciences, cannabidiol, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Medicine, Doxorubicin, Cardioprotective Agent, Adverse effect, ComputingMilieux_MISCELLANEOUS, Cardiotoxicity, galanin, business.industry, medicine.disease, Prokineticin, 3. Good health, Apelin, prokineticin, 030104 developmental biology, Drug development, apelin, lcsh:RC666-701, ghrelin, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, business, Cardiology and Cardiovascular Medicine, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, medicine.drug |
| الوصف: | Novel anticancer medicines, including targeted therapies and immune checkpoint inhibitors, have greatly improved the management of cancers. However, both conventional and new anticancer treatments induce cardiac adverse effects, which remain a critical issue in clinic. Cardiotoxicity induced by anti-cancer treatments compromise vasospastic and thromboembolic ischemia, dysrhythmia, hypertension, myocarditis, and cardiac dysfunction that can result in heart failure. Importantly, none of the strategies to prevent cardiotoxicity from anticancer therapies is completely safe and satisfactory. Certain clinically used cardioprotective drugs can even contribute to cancer induction. Since G protein coupled receptors (GPCRs) are target of forty percent of clinically used drugs, here we discuss the newly identified cardioprotective agents that bind GPCRs of adrenalin, adenosine, melatonin, ghrelin, galanin, apelin, prokineticin and cannabidiol. We hope to provoke further drug development studies considering these GPCRs as potential targets to be translated to treatment of human heart failure induced by anticancer drugs. journal article review 2019 2020 01 24 imported |
| اللغة: | English |
| تدمد: | 2297-055X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7557d7b7bac4476e427a3151ec04c901Test https://www.frontiersin.org/article/10.3389/fcvm.2019.00194/fullTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....7557d7b7bac4476e427a3151ec04c901 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 2297055X |
|---|